期刊
EXPERIMENTAL HEMATOLOGY
卷 60, 期 -, 页码 47-56出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.exphem.2018.01.003
关键词
-
资金
- Heilongjiang Health and Family Planning Commission [2017-129]
- Harbin Medical University [2017LCZX82]
- Haiyan program of Harbin Medical University Cancer Hospital [JJZD2014-08, JJQN2016-04]
Immunotherapy results in lymphoma have been encouraging. Preclinical and clinical trials have proven checkpoint blockade, such as PD-1 antibody, as an effective treatment for lymphoma, including diffuse large B-cell lymphoma (DLBCL). Combination of checkpoint blockades has emerged as a new way to treat lymphoma; however, the status of checkpoint expression and their function in DLBCL have not been fully elucidated yet. In this study, we examined the expression of BTLA, PD-1, TIM-3, LIGHT, and LAG-3 in tumor microenvironmental T cells of DLBCL using flow cytometry and compared the cytotoxicity and differentiation status of BTLA(+) and BTLA(-) T-cells. We further characterized the relationship of STAT3 phosphorylation (p-STAT3) with BTLA expression. Our results suggest that BTLA(+) T cells highly express other checkpoint molecules, including PD-1, TIM-3, LIGHT, and LAG-3. Moreover, high expression of BTLA is correlated with advanced stage of DLBCL. BTLA(+) T cells have a less differentiated phenotype, lower cytolytic function, and higher potential to proliferate compared with BTLA(-) T cells. Taken together, our data provide the first evidence that increased BTLA predicts poor prognosis in patients with DLBCL, and blockade of BTLA with other checkpoints may potentially represent a new strategy for immunotherapy of DLBCL. (C) 2018 Published by Elsevier Inc. on behalf of ISEH - Society for Hematology and Stem Cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据